Get started
Author

Catherine E. Ellis

Observed name: Catherine Ellis
ORCID: 0009-0008-7635-7846
Observed ORCID: 0009-0008-7635-7846
OpenAlex ID: A5073127295
Activating Inducible T-cell Costimulator Yields Antitumor Activity Alone and in Combination with Anti-PD-1 Checkpoint Blockade
2023 · Sapna Yadavilli, Jeremy D. Waight, et al. · Cancer Research Communications · 17
PDF
Momelotinib: Mechanism of action, clinical, and translational science
2024 · Georgios Vlasakakis, Michael T. McCabe, et al. · Clinical and Translational Science · 14
PDF
Anemia-related response end points in myelofibrosis clinical trials: current trends and need for renewed consensus
2024 · Barbara J Klencke, Rafe Donahue, et al. · Future Oncology · 10
Anemia in Myelofibrosis: A Focus on Proactive Management and the Role of Momelotinib
2024 · Haifa Kathrin Al-Ali, Andrew T. Kuykendall, et al. · Cancers · 9
PDF
Myelofibrosis symptom assessment form total symptom score version 4.0: measurement properties from the MOMENTUM phase 3 study
2024 · Christina Daskalopoulou, Boris Gorsh, et al. · Quality of Life Research · 7
PDF
Longitudinal Assessment of Transfusion Intensity in Patients With JAK Inhibitor–Naive or –Experienced Myelofibrosis Treated With Momelotinib
2024 · Claire N. Harrison, Ruben Mesa, et al. · Clinical Lymphoma Myeloma & Leukemia · 6
CITRINO: phase 1 dose escalation study of anti-LAG-3 antibody encelimab alone or in combination with anti-PD-1 dostarlimab in patients with advanced/metastatic solid tumours
2025 · J. Randolph Hecht, Jean-Marie Michot, et al. · BJC Reports · 2
Optimized dosing of momelotinib in myelofibrosis through quantitative medicine: a clinical commentary
2026 · Georgios Vlasakakis, Fernando Carreño, et al. · Leukemia & lymphoma/Leukemia and lymphoma
PDF
Supplementary Table S1 from INDUCE-3: A Randomized Phase II/III Study of First-line Feladilimab plus Pembrolizumab in Patients with Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma
2026 · Danny Rischin, Aaron R. Hansen, et al.
Supplementary Figure S1 from INDUCE-3: A Randomized Phase II/III Study of First-line Feladilimab plus Pembrolizumab in Patients with Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma
2026 · Danny Rischin, Aaron R. Hansen, et al.
Table 2 from INDUCE-3: A Randomized Phase II/III Study of First-line Feladilimab plus Pembrolizumab in Patients with Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma
2026 · Danny Rischin, Aaron R. Hansen, et al.
Supplementary Figure S2 from INDUCE-3: A Randomized Phase II/III Study of First-line Feladilimab plus Pembrolizumab in Patients with Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma
2026 · Danny Rischin, Aaron R. Hansen, et al.
Supplementary Figure S3 from INDUCE-3: A Randomized Phase II/III Study of First-line Feladilimab plus Pembrolizumab in Patients with Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma
2026 · Danny Rischin, Aaron R. Hansen, et al.
Table 3 from INDUCE-3: A Randomized Phase II/III Study of First-line Feladilimab plus Pembrolizumab in Patients with Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma
2026 · Danny Rischin, Aaron R. Hansen, et al.
Table 1 from INDUCE-3: A Randomized Phase II/III Study of First-line Feladilimab plus Pembrolizumab in Patients with Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma
2026 · Danny Rischin, Aaron R. Hansen, et al.
Data from INDUCE-3: A Randomized Phase II/III Study of First-line Feladilimab plus Pembrolizumab in Patients with Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma
2026 · Danny Rischin, Aaron R. Hansen, et al.
Supplementary Table S3 from INDUCE-3: A Randomized Phase II/III Study of First-line Feladilimab plus Pembrolizumab in Patients with Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma
2026 · Danny Rischin, Aaron R. Hansen, et al.
Figure 1 from INDUCE-3: A Randomized Phase II/III Study of First-line Feladilimab plus Pembrolizumab in Patients with Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma
2026 · Danny Rischin, Aaron R. Hansen, et al.
Supplementary Table S5 from INDUCE-3: A Randomized Phase II/III Study of First-line Feladilimab plus Pembrolizumab in Patients with Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma
2026 · Danny Rischin, Aaron R. Hansen, et al.
Figure 2 from INDUCE-3: A Randomized Phase II/III Study of First-line Feladilimab plus Pembrolizumab in Patients with Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma
2026 · Danny Rischin, Aaron R. Hansen, et al.
Supplementary Table S2 from INDUCE-3: A Randomized Phase II/III Study of First-line Feladilimab plus Pembrolizumab in Patients with Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma
2026 · Danny Rischin, Aaron R. Hansen, et al.
Supplementary Table S4 from INDUCE-3: A Randomized Phase II/III Study of First-line Feladilimab plus Pembrolizumab in Patients with Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma
2026 · Danny Rischin, Aaron R. Hansen, et al.
Figure 3 from INDUCE-3: A Randomized Phase II/III Study of First-line Feladilimab plus Pembrolizumab in Patients with Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma
2026 · Danny Rischin, Aaron R. Hansen, et al.
Evaluation of the Effect of Momelotinib on Cardiac Repolarization: A Thorough QT Study
2025 · Georgios Vlasakakis, Yolanda Alvarez, et al. · Clinical Pharmacology in Drug Development
PDF
Supplementary Figure 10 from Activating Inducible T-cell Costimulator Yields Antitumor Activity Alone and in Combination with Anti-PD-1 Checkpoint Blockade
2023 · Sapna Yadavilli, Jeremy D. Waight, et al.
Works count: 121
Citation count: 65
H-index: 6
I10-index: 3
Year
Topic
Type